Direct nanopore sequencing of non-coding RNA for early-stage cancer and precancer detection

Technology
In development
University
Scouted & summarized by Halo AI

A breakthrough liquid biopsy platform that uses long-read nanopore sequencing to analyze non-coding cell-free RNA for the highly sensitive detection of early-stage cancer and precancerous conditions. The technology enables the discovery of novel drug targets for disease interception and is compatible with portable, handheld sequencing devices for flexible clinical and research applications.

Overview

This liquid biopsy platform leverages direct, long-read nanopore sequencing of full-length cell-free RNA (cfRNA) from plasma to detect early-stage cancer and precancerous conditions. By targeting non-coding "dark matter" RNA—genetic material often overlooked by standard sequencing—the platform provides high sensitivity and specificity for early-stage disease detection, where biological signals are typically low. Beyond diagnostics, the technology identifies dysregulated molecular pathways, enabling the discovery of novel drug targets for therapeutic interception.

Technical specifications
  • Sequencing Methodology: Employs long-read nanopore sequencing to analyze the full length of cfRNA, providing deeper insight into the transcriptome than traditional short-read methods.
  • Diagnostic Platform: Integrates machine learning models trained on unique RNA features and novel intergenic transcripts to classify disease states accurately.
  • Portability: Compatible with handheld devices such as the Oxford Nanopore MinION, facilitating potential use in diverse clinical and remote settings.
  • Analytical Depth: Capable of detecting both protein-coding and non-coding, repetitive RNA elements, significantly enhancing the biological signal for early-stage tumor detection.
  • Clinical Utility: Validated in research studies for early detection of esophageal cancer and Barrett's esophagus; broadly applicable to other cancer types and diseases that alter the RNA landscape.
Technology readiness level

The technology is currently at TRL 5. It has moved beyond conceptualization to laboratory validation and demonstration, with success in identifying novel biomarkers and classifying patient samples (healthy, precancerous, and cancer) in research cohorts. The platform is now entering a phase of expanded assessment in larger patient populations through a strategic research partnership with Oxford Nanopore Technologies to advance clinical utility.

Generated Jul 8, 2026. Please verify key information.

About University of California, Santa Cruz

UC Santa Cruz is a public land‑grant research university in Santa Cruz, California, recognized for interdisciplinary collaboration within the University of California system. Its Silicon Valley campus in Santa Clara places programs and engagement in the heart of the tech cluster. On the main campus and at the Westside Research Park, shared facilities and collaborative spaces connect faculty with companies for joint development and translation. Research is supported by competitive federal agencies, including NSF, NIH, DOE, and NASA, and strengthened by longstanding collaboration with NASA Ames. Industry partnership and tech transfer—through the Innovation & Business Engagement Hub, the Industry Alliances & Technology Commercialization office, and UC’s systemwide network—streamline IP, sponsored research, and startups.

Halo home
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.